A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
Public ClinicalTrials.gov record NCT02671435. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors
Study identification
- NCT ID
- NCT02671435
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 383 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- Cetuximab Drug
- Durvalumab Drug
- Monalizumab Drug
- mFOLFOX6 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2016
- Primary completion
- Oct 25, 2021
- Completion
- Aug 31, 2025
- Last update posted
- Jul 21, 2025
2016 – 2025
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35233 | — |
| Research Site | Scottsdale | Arizona | 85258 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Los Angeles | California | 90089 | — |
| Research Site | Sacramento | California | 95817 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Baltimore | Maryland | 21231 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | New Brunswick | New Jersey | 08903 | — |
| Research Site | New Hyde Park | New York | 11042 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | Providence | Rhode Island | 02903 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02671435, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02671435 live on ClinicalTrials.gov.